Showing 371-380 of 1779 results for "".
Asked and Answered: Pro Tips for Writing FAQ Pages
https://reachmd.com/ma-issues-index/2022-nov-dec/asked-and-answered/35235/Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
https://reachmd.com/programs/neurofrontiers/safety-and-efficacy-of-onasemnogene-abeparvovec-in-pediatric-sma-across-expanded-weight-cohorts/36614/Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
https://reachmd.com/clinical-practice/cardiology/evolocumab-in-patients-without-significant-atherosclerosis-and-with-diabetes-a-cardiology-perspective-on-vesalius-cv/56744/New VESALIUS-CV data show broad cardiovascular benefits of evolocumab in high-risk primary prevention patients with diabetes and no atherosclerosis.Efgartigimod Shows Early Promise for Primary Sjögren’s Disease
https://reachmd.com/programs/living-rheum/efgartigimod-shows-early-promise-for-primary-sjogrens-disease/36333/Seltorexant vs Quetiapine XR in MDD With Insomnia: A 26-Week Phase 3 Comparison
https://reachmd.com/clinical-practice/psychiatry-and-mental-health/seltorexant-vs-quetiapine-xr-in-mdd-with-insomnia-a-26-week-phase-3-comparison/37644/Compare efficacy, safety, and tolerability of adjunctive seltorexant versus quetiapine XR in MDD patients with insomnia symptoms.Sustained Antidepressant and Sleep Benefits With Adjunctive Seltorexant in MDD: Double-Blind and Long-Term Extension Data From the MD3001 Trial
https://reachmd.com/clinical-practice/psychiatry-and-mental-health/sustained-antidepressant-and-sleep-benefits-with-adjunctive-seltorexant-in-mdd-double-blind-and-long-term-extension-data-from-the-md3001-trial/36555/Review Phase 3 MD3001 trial data on adjunctive seltorexant in MDD with insomnia, including double-blind efficacy and 1-year extension safety outcomes.Valbenazine for TD: Consistent Long-Term Efficacy Across Racial and Ethnic Subgroups in KINECT-4
https://reachmd.com/clinical-practice/psychiatry-and-mental-health/valbenazine-for-td-consistent-long-term-efficacy-across-racial-and-ethnic-subgroups-in-kinect-4/37642/Valbenazine for TD: Consistent Long-Term Efficacy Across Racial and Ethnic Subgroups in KINECT-4Valbenazine and Patient-Centered Outcomes in TD: Insights From the KINECT-PRO Study
https://reachmd.com/clinical-practice/psychiatry-and-mental-health/valbenazine-and-patient-centered-outcomes-in-td-insights-from-the-kinect-pro-study/36175/Valbenazine and Patient-Centered Outcomes in TD: Insights From the KINECT-PRO StudyA Clinician's Guide to the ACIP Travel Vaccination Recommendations
https://reachmd.com/programs/vaccination/a-clinicians-guide-to-the-acip-travel-vaccination-recommendations/26483/Get ready to integrate the latest ACIP updates into practice to improve patient care and public health outcomes with this essential recap.Surge (Dynamic) Pricing Is Here
https://reachmd.com/topics/practice-development/surge-dynamic-pricing-is-here/35131/As inflation affects costs for goods and services, aesthetics practices may benefit from dynamic pricing for certain services